BGOG

ENGOT-EN20/GOG-3083/XPORT-EC-042

A Phase 3, Randomized, Placebo-Controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced or recurrent endometrial carcinoma

Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

ENGOT-EN11/GOG-3053/KEYNOTE-B21

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus placebo in combination with adjuvant chemotherapy with or without radiotherapy for the treatment of newly diagnosed High-Risk Endometrial Cancer after surgery with curative Intent

Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

ENGOT-ov50/GOG-3029/INNOVATE-3

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer

Trial Number
NCT03940196
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

ENGOT-ov43/GOG-3036/MK-7339

A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) 

Trial Number
NCT03740165
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

ENGOT-cx12/GOG-3037/SNGTV-003

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

ENGOT-cx8/ GOG-3024/GCT1015-05

A Phase 1b/2 open-Label Trial of Tisotumab Vedotin (Humax-TF-ADC) Monotherapy and in combination with other Agents in Subjects with recurrent or Stage IVB Cervical Cancer

Trial Number
NCT03786081
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

ENGOT-cx1/BGOG-cx1

Randomized double-blind Phase II study comparing carboplatin + paclitaxel with or without concomitant and maintenance Nintedanib in advanced or recurrent cervical carcinoma

Trial Number
NCT02009579
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number